Identification of a chromatin regulator signature in prognosis and immune infiltration in breast cancer-Reference-Cited by-同舟云学术

Identification of a chromatin regulator signature in prognosis and immune infiltration in breast cancer

Published:2022-10-03 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Zhang Weiran¹,Song Hongming¹,Xia Jing²,Huan Yuqi¹,Wang Xiaowei¹,Kong Bin¹

Affiliation:

1. Qingdao University

2. Qingdao Center Hospital: Qingdao Center Medical Group

Abstract

Abstract Background: Chromatin regulators (CRs) are indispensable upstream regulatory factors of epigenetics and play an important role in cancer progression. Herein, we explored the relationship between CRs and breast cancer (BC) through bioinformatics to improve BC prognosis and treatment. Methods: The RNA sequencing (RNA-seq) profiles and clinical data were retrieved from the Gene Expression Omnibus (GEO) database. Univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO) regression were used to build a prognostic model. Patients were divided into high and low-risk groups according to the risk score. Then, a nomogram was constructed based on the selected clinical features and risk score. The differences in immune cell infiltration and checkpoints were estimated for the high and low-risk groups. Results: We established and validated a prognostic model of BC patients based on 4 CRs-related genes (MORF4L1, NCOA4, TTK and JMJD4). The high-risk group presented poor prognosis. The immune-correlation analysis also showed that the high-risk group might response to immunotherapy. Conclusion: We successfully established a reliable 4 CRs-related prognostic model and provided novel insights for evaluating immune infiltration and guiding the treatment of BC patients.

Publisher

Research Square Platform LLC

Reference57 articles.

1. 1. Zeng L, Li W, Chen CS: Breast cancer animal models and applications. Zoological research 2020, 41(5):477-494https://doi.org/10.24272/j.issn.2095-8137.2020.095.

2. 2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians 2018, 68(6):394-424https://doi.org/10.3322/caac.21492.

3. 3. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2020. CA: a cancer journal for clinicians 2020, 70(1):7-30https://doi.org/10.3322/caac.21590.

4. 4. DeRose YS, Wang G, Lin YC, Bernard PS, Buys SS, Ebbert MT, Factor R, Matsen C, Milash BA, Nelson E et al: Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nature medicine 2011, 17(11):1514-1520https://doi.org/10.1038/nm.2454.

5. 5. Liu Q, Ma JY, Wu G: Identification and validation of a ferroptosis-related gene signature predictive of prognosis in breast cancer. Aging 2021, 13(17):21385-21399https://doi.org/10.18632/aging.203472.